Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Asset Writedowns and Impairment (2023 - 2025)

Historic Asset Writedowns and Impairment for Autolus Therapeutics (AUTL) over the last 3 years, with Q3 2025 value amounting to $4.3 million.

  • Autolus Therapeutics' Asset Writedowns and Impairment changed N/A to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 1350000.0%. This contributed to the annual value of $414000.0 for FY2024, which is 350.0% up from last year.
  • Latest data reveals that Autolus Therapeutics reported Asset Writedowns and Impairment of $4.3 million as of Q3 2025.
  • In the past 5 years, Autolus Therapeutics' Asset Writedowns and Impairment ranged from a high of $4.3 million in Q3 2025 and a low of -$382000.0 during Q3 2023
  • Over the past 3 years, Autolus Therapeutics' median Asset Writedowns and Impairment value was $414000.0 (recorded in 2024), while the average stood at $1.4 million.
  • Data for Autolus Therapeutics' Asset Writedowns and Impairment shows a peak YoY increase of 50386.47% (in 2025) and a maximum YoY decrease of 50386.47% (in 2025) over the last 5 years.
  • Quarter analysis of 3 years shows Autolus Therapeutics' Asset Writedowns and Impairment stood at $18000.0 in 2023, then soared by 2200.0% to $414000.0 in 2024, then surged by 938.65% to $4.3 million in 2025.
  • Its Asset Writedowns and Impairment was $4.3 million in Q3 2025, compared to $2.5 million in Q2 2025 and $414000.0 in Q2 2024.